Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

Cited by (1,000)

Items 101–200 of 1,000

1. Targeting WNT signaling in the treatment of osteoporosis
   Baron, Roland, Gori, Francesca · 2018 · Current Opinion in Pharmacology
2. Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society
   Denise M van de Laarschot, Malachi J. McKenna, Bo Abrahamsen, Bente Lomholt Langdahl, Martine Esther Cohen-Solal, Núria Guañabens, Richard Eastell, Stuart H. Ralston, M. Carola Zillikens · 2019 · The Journal of Clinical Endocrinology & Metabolism
3. Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis
   Eben G. Estell, Clifford james Rosen · 2020 · Nature Reviews Endocrinology
4. Management of patients at very high risk of osteoporotic fractures through sequential treatments
   Elizabeth Mary Curtis, Jean‐Yves Reginster, Nasser M. Al‐Daghri, Emmanuel Biver, Maria Luisa Brandi, Etienne Cavalier, Peyman Hadji, Philippe Halbout, Nicholas C. Harvey, Mickaël Hiligsmann et al. · 2022 · Aging Clinical and Experimental Research
5. Osteoporosis in 10 years time: a glimpse into the future of osteoporosis
   Giovanni Adami, Angelo Fassio, Davide Gatti, Ombretta Viapiana, Camilla Benini, Maria I. Danila, Kenneth G. Saag, Maurizio Rossini · 2022 · Therapeutic Advances in Musculoskeletal Disease
6. Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones
   Jialiang S. Wang, Courtney M. Mazur, Marc Nathan Wein · 2021 · Frontiers in Endocrinology
7. Bone health and menopause: Osteoporosis prevention and treatment
   Tobie J. de Villiers · 2023 · Best Practice & Research Clinical Endocrinology & Metabolism
8. Osteoporosis Management in the Era of COVID-19
   Elaine Wei-Yin Yu, Elena A. Tsourdi, Bart Lyman Clarke, Douglas C. Bauer, Matthew T. Drake · 2020 · Journal of Bone and Mineral Research
9. Skeletal Aging
   Jad G. Sfeir, Matthew T. Drake, Sundeep Khosla, Joshua N. Farr · 2022 · Mayo Clinic Proceedings
10. The role of miR‐29 family in disease
    Masahiro Horita, Colin Farquharson, Louise A. Stephen · 2021 · Journal of Cellular Biochemistry
11. Osteoporosis in older adults
    Béatrice Bouvard, Cédric Annweiler, Érick Legrand · 2021 · Joint Bone Spine
12. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease
    Paul D. Miller, Jonathan Derrick Adachi, Ben‐Hur Albergaria, Angela M. Cheung, Arkadi A. Chines, Evelien Gielen, Bente Lomholt Langdahl, Akimitsu Miyauchi, Mary K. Oates, Ian R. Reid et al. · 2020 · Journal of Bone and Mineral Research
13. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab—a review
    Rebecca King, Nikki Tanna, Vinod Patel · 2018 · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology
14. Novel actions of sclerostin on bone
    Gill Holdsworth, Scott J. Roberts, Hua Zhu Ke · 2018 · Journal of Molecular Endocrinology
15. Osteoporosis therapies and their mechanisms of action (Review)
    Beomchang Kim, Yong Cho, Wonbong Lim · 2021 · Experimental and Therapeutic Medicine
16. Osteoanabolic Agents for Osteoporosis
    Andrea V Haas, Meryl Susan LeBoff · 2018 · Journal of the Endocrine Society
17. Postmenopausal osteoporosis: Assessment and management
    René Rizzoli · 2018 · Best Practice & Research Clinical Endocrinology & Metabolism
18. Osteogenesis Imperfecta: Current and Prospective Therapies
    Malwina Botor, Agnieszka Fus-Kujawa, Marta Uroczynska, Karolina Stępień, Anna Galicka, Katarzyna Gawron, Aleksander L. Sieroń · 2021 · Biomolecules
19. On the utilization of polygenic risk scores for therapeutic targeting
    Greg C. Gibson · 2019 · PLoS Genetics
20. The critical interplay between bone resorbing and bone forming cells
    Ulf H. Lerner, Elin Kindstedt, Pernilla Lundberg · 2019 · Journal Of Clinical Periodontology
21. Crosstalk between the gut microbiota and postmenopausal osteoporosis: Mechanisms and applications
    Qin Xu, Dan Li, Jing Chen, Ju Yang, Jiai Yan, Yanping Xia, Feng Zhang, Xuesong Wang, Hong Cao · 2022 · International Immunopharmacology
22. Primary Osteoporosis Induced by Androgen and Estrogen Deficiency: The Molecular and Cellular Perspective on Pathophysiological Mechanisms and Treatments
    Shao-Heng Hsu, Li-Ru Chen, Kuo-Hu Chen · 2024 · International Journal of Molecular Sciences
23. Osteoporosis
    Carrie Ye, Peter Robert Ebeling, Gregory A. Kline · 2025 · The Lancet
24. Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates
    Anne M. Horne, Borislav Mihov, Ian R. Reid · 2018 · Calcified Tissue International
25. Sclerostin: from bench to bedside
    Sakae Tanaka, Toshio Matsumoto · 2020 · Journal of Bone and Mineral Metabolism
26. A Wnt-Responsive PDL Population Effectuates Extraction Socket Healing
    Xue Yuan, Xibo Pei, Yuan Zhao, U.S. Tulu, B. Liu, Jill Ann Helms · 2018 · Journal of Dental Research
27. Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women
    Ian R. Reid, Anne M. Horne, Borislav Mihov, Angela Stewart, Elizabeth Garratt, Sonja Bastin, Greg D. Gamble · 2019 · Journal of Bone and Mineral Research
28. A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis
    Surjit Singh, Siddhartha Dutta, Sameer Uttamaro Khasbage, Tarun Kumar, J. Sachin, Jyoti Sharma, Shoban Babu Varthya · 2021 · Osteoporosis International
29. Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes
    Manuel Gado, Ulrike Baschant, Lorenz Christian Hofbauer, Holger Henneicke · 2022 · Frontiers in Endocrinology
30. Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice
    Luyao Wang, Yuanyuan Yu, Shuaijian Ni, Dijie Li, Jin Liu, Duoli Xie, Hang Yin Chu, Qing Ren, Chuanxin Zhong, Ning Zhang et al. · 2022 · Theranostics
31. Osteoanabolic and dual action drugs
    Gaia Tabacco, John Paul Bilezikian · 2018 · British Journal of Clinical Pharmacology
32. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches
    Bente Lomholdt Langdahl · 2020 · Bone
33. MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis
    ERNESTO M. CANALIS · 2017 · European Journal of Endocrinology
34. Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation
    Mickaël Hiligsmann, Jean‐Yves Reginster, Anna N.A. Tosteson, Susan V. Bukata, Kenneth G. Saag, Deborah T. Gold, Philippe Halbout, Famida Jiwa, Edward Michael Lewiecki, Daniel Pinto et al. · 2018 · Osteoporosis International
35. Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures
    J. A. Kanis, Helena Johansson, Nicholas C. Harvey, Vilmundur G. Gudnason, Gunnar Sigurðsson, Kristín Siggeirsdóttir, Mattias Lorentzon, Enwu Liu, Liesbeth Vandenput, Eugene Vincent McCloskey · 2020 · Osteoporosis International
36. Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy
    Benjamin Z. Leder · 2018 · JBMR Plus
37. A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
    Emil H. Schemitsch, Theodore Miclau, Theofilos S. Karachalios, Lauren L. Nowak, Parag Kantilal Sancheti, Rudolf Wilhelm Poolman, John N Caminis, Nadia S Daizadeh, Ricardo E. Dent-Acosta, Ogo I. Egbuna et al. · 2020 · Journal of Bone and Joint Surgery
38. Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Annika Vestergaard Kvist, Junaid Faruque, Enriqueta Vallejo‐Yagüe, Stefan Weiler, Elizabeth Martha Winter, Andrea Michelle Burden · 2021 · Journal of Clinical Medicine
39. Recent Progresses in the Treatment of Osteoporosis
    Shanshan Li, Shi‐Hao He, Peng-yu Xie, Wei Li, Xinxin Zhang, Tian-Fang Li, Daifeng Li · 2021 · Frontiers in Pharmacology
40. Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment
    Mathias Loberg Haarhaus, Pieter Evenepoel · 2021 · Kidney International
41. Crosstalk of Brain and Bone—Clinical Observations and Their Molecular Bases
    Ellen Otto, P. Knapstein, Denise Jahn, Jessika Appelt, Karl‐Heinz Frosch, Serafeim Tsitsilonis, Johannes Keller · 2020 · International Journal of Molecular Sciences
42. Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis
    Ramchand, Sabashini K, Leder, Benjamin Z · 2024 · The Journal of Clinical Endocrinology & Metabolism
43. Romosozumab in osteoporosis: yesterday, today and tomorrow
    Dong Wu, Lei Li, Zhun Wen, Guangbin Wang · 2023 · Journal of Translational Medicine
44. Understanding and managing corticosteroid-induced osteoporosis
    Kobza, Alexandra O, Herman, Deena, Papaioannou, Alexandra, Lau, Arthur N, Adachi, Jonathan D · 2021 · Open Access Rheumatology Research and Reviews
45. Romosozumab: First Global Approval
    Anthony Markham · 2019 · Drugs
46. Bone health in diabetes and prediabetes
    Silvia Costantini, Caterina Conte · 2019 · World Journal of Diabetes
47. Skeletal responses to romosozumab after 12 months of denosumab
    Michael R. McClung, Michael A. Bolognese, Jacques P. Brown, Jean‐Yves Reginster, Bente Lomholt Langdahl, Yifei Shi, Jen Timoshanko, Cesar R. Libanati, Arkadi A. Chines, Mary K. Oates · 2021 · JBMR Plus
48. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone
    Takahiko Shibahara · 2019 · The Tohoku Journal of Experimental Medicine
49. Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome
    Felicia Cosman, Daria B. Crittenden, Serge Ferrari, Edward Michael Lewiecki, Juan José Jaller-Raad, Cristiano A. F. Zerbini, Cassandra E. Milmont, Paul D Meisner, Cesar R. Libanati, Andreas Grauer · 2018 · Journal of Bone and Mineral Research
50. Pharmacological Therapy of Osteoporosis: What’s New?
    Giovanni Iolascon, Antimo Moretti, Giuseppe Toro, Francesca Gimigliano, Sara Liguori, Marco Paoletta · 2020 · Clinical Interventions in Aging
51. A Review of Osteoporosis in the Older Adult
    Paloma Alejandro, Florina Constantinescu · 2018 · Rheumatic Disease Clinics of North America
52. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models
    Aimy Sebastian, Gabriela G. Loots · 2017 · Metabolism
53. Sclerostin as Regulatory Molecule in Vascular Media Calcification and the Bone–Vascular Axis
    Annelies De Maré, Stuart R. Maudsley, Abdelkrim Azmi, Jhana O. Hendrickx, Britt Opdebeeck, Ellen Neven, Patrick C. D’Haese, Anja Verhulst · 2019 · Toxins
54. Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk
    Cy W. Fixen, Jennifer Tunoa · 2021 · Current Osteoporosis Reports
55. Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial
    Jacques P. Brown, Klaus Engelke, Tony M. Keaveny, Arkadi A. Chines, Roland D Chapurlat, A. Joseph Foldes, Xavier Nogués, Roberto Civitelli, Tobias De Villiers, Fabio Massari et al. · 2021 · Journal of Bone and Mineral Research
56. Bone-Vascular Axis in Chronic Kidney Disease
    Pieter Evenepoel, Britt Opdebeeck, Karel David, Patrick C. D’Haese · 2019 · Advances in Chronic Kidney Disease
57. Romosozumab for the treatment of osteoporosis
    McClung, Michael R. · 2018 · Osteoporosis and Sarcopenia
58. Melatonin prevents bone destruction in mice with retinoic acid–induced osteoporosis
    Xudong Wang, Tongzhou Liang, Yuanxin Zhu, Jincheng Qiu, Xianjian Qiu, Chengjie Lian, Bo Gao, Yan Peng, Anjing Liang, Hang Zhou et al. · 2019 · Molecular Medicine
59. Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains
    Jinuk Kim, Wonhee Han, Taeyong Park, Eun‐Jin Kim, Injin Bang, Hyun Sik Lee, Yejin Jeong, Kyeonghwan Roh, Jeesoo Kim, Jong‐Seo Kim et al. · 2020 · Nature Communications
60. Osteoporosis: Current and Emerging Therapies Targeted to Immunological Checkpoints
    Massimo De Martinis, Maria Maddalena Sirufo, Lia Ginaldi · 2019 · Current Medicinal Chemistry
61. Osteoporosis Treatment with Anti-Sclerostin Antibodies—Mechanisms of Action and Clinical Application
    Martina Rauner, Hanna Taipaleenmäki, Elena A. Tsourdi, Elizabeth Martha Winter · 2021 · Journal of Clinical Medicine
62. Management of Osteoporosis and Spinal Fractures: Contemporary Guidelines and Evolving Paradigms
    Nasvin Imamudeen, Amjad Basheer, Anoop Mohamed Iqbal, Nihal Manjila, Nisha Nigil Haroon, Sunil V. Manjila · 2022 · Clinical Medicine & Research
63. Treatment of Osteoporosis and Osteoarthritis in the Oldest Old
    Nicholas R. Fuggle, Andrea Laslop, René Rizzoli, Nasser M. Al‐Daghri, Majed Saleh Alokail, Ewa Bałkowiec-Iskra, Charlotte Beaudart, Olivier Bruyère, Angie Botto‐van Bemden, Nansa Burlet et al. · 2025 · Drugs
64. Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases
    Stéphanie Fabre, Thomas Funck‐Brentano, Martine Esther Cohen-Solal · 2020 · Journal of Clinical Medicine
65. Sclerostin in chronic kidney disease–mineral bone disorder think first before you block it!
    Vincent Matthias Brandenburg, Anja Verhulst, Anne Babler, Patrick C. D’Haese, Pieter Evenepoel, Nadine Kaesler · 2018 · Nephrology Dialysis Transplantation
66. Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis
    Antonio Naranjo, Petra Díaz del Campo Fontecha, María Pilar Aguado Acín, Luis Marcelino Arboleya Rodríguez, E. Casado, Santos Castañeda, Jordi Fiter Aresté, Laia Gifre, Carmen Gómez Vaquero, Gloria Candelas et al. · 2018 · Reumatología Clínica
67. ACOG Clinical Practice Guideline No. 2: Management of Postmenopausal Osteoporosis
    Swan Sim Yeap, FL Hew, S-P Chan · 2022 · Obstetrics and Gynecology
68. Skeletal and extraskeletal disorders of biomineralization
    Michael Terrence Collins, Gemma Marcucci, Hans‐Joachim Anders, Giovanni Beltrami, Jane A. Cauley, Peter Robert Ebeling, Rajiv Kumar, Agnès Linglart, Luca Sangiorgi, Dwight A. Towler et al. · 2022 · Nature Reviews Endocrinology
69. Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases
    Frank Buttgereit, Andriko Palmowski, Milena Bond, Giovanni Adami, Christian Dejaco · 2024 · Nature Reviews Rheumatology
70. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis
    Kosuke Ebina, Makoto Hirao, Hideki Tsuboi, Yoshio Nagayama, Masafumi Kashii, Shoichi Kaneshiro, Akira Miyama, Hiroyuki Nakaya, Yasuo Kunugiza, Gensuke Okamura et al. · 2020 · Bone
71. Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations
    Jingbo Xie, Jian Guo, Zaeema Kanwal, Mingzheng Wu, Xiangyang Lv, Nihal Abdalla Ibrahim, Ping Li, Manal Ali Buabeid, El‐Shaimaa A. Arafa, Qingshan Sun · 2020 · International Journal of Endocrinology
72. Advances in the management of osteoporosis
    Caroline Wei Shan Hoong, Dominik Saul, Sundeep Khosla, Jad G. Sfeir · 2025 · BMJ
73. Epigenetic regulation of bone remodeling by natural compounds
    Nishikant A. Raut, Sheila M. Wicks, Tempitope O. Lawal, Gail B. Mahady · 2019 · Pharmacological Research
74. Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project
    Richard Eastell, Eric Vittinghoff, Li‐Yung Lui, Charles E. McCulloch, Imre J. Pavo, Arkadi A. Chines, Sundeep Khosla, Jane A. Cauley, Bruce Mitlak, Douglas C. Bauer et al. · 2020 · Journal of Bone and Mineral Research
75. The multi-faceted nature of age-associated osteoporosis
    Annelies E. Smit, Onno Cornelis Meijer, Elizabeth Martha Winter · 2024 · Bone Reports
76. Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway
    Natasha M. Appelman‐Dijkstra, Socrates E. Papapoulos · 2018 · Nature Reviews Endocrinology
77. Glycyrrhizic acid suppresses osteoclast differentiation and postmenopausal osteoporosis by modulating the NF-κB, ERK, and JNK signaling pathways
    Ziqing Yin, Wei Zhu, Qi Wu, Qiang Zhang, Shuangfei Guo, Tang Liu, Shuai Li, Xia Chen, Dan Peng, Zhengxiao Ouyang · 2019 · European Journal of Pharmacology
78. From latency to overt bone metastasis in breast cancer: potential for treatment and prevention
    Fernando Salvador, Alicia Llorente Lope, Roger R. Gomis · 2019 · The Journal of Pathology
79. The NO–cGMP–PKG pathway in skeletal remodeling
    Se‐Min Kim, Tony Yuen, Jameel Z. Iqbal, Mishaela Ruth Rubin, Mone Zaidi · 2020 · Annals of the New York Academy of Sciences
80. Mechanistic Insights and Therapeutic Strategies in Osteoporosis: A Comprehensive Review
    Nyruz Ramadan Elahmer, Sok Kuan Wong, Norazlina Mohamed, Ekram Alias, Kok‐Yong Chin, Norliza Muhammad · 2024 · Biomedicines
81. Contributors to impaired bone health in type 2 diabetes
    Sheu, Angela, Greenfield, Jerry R., White, Christopher P., Center, Jacqueline R. · 2023 · Trends in Endocrinology & Metabolism
82. The crisis of inadequate treatment in osteoporosis
    Christian Roux, Karine Briot · 2020 · The Lancet Rheumatology
83. Sclerostin Protects Against Vascular Calcification Development in Mice
    Annelies De Maré, Britt Opdebeeck, Ellen Neven, Patrick C. D’Haese, Anja Verhulst · 2020 · Journal of Bone and Mineral Research
84. Osteoporosis in 2022: Care gaps to screening and personalised medicine
    Elizabeth Mary Curtis, Elaine Margaret Dennison, Cyrus C. Cooper, Nicholas C. Harvey · 2022 · Best Practice & Research Clinical Rheumatology
85. MicroRNA-29a represses osteoclast formation and protects against osteoporosis by regulating PCAF-mediated RANKL and CXCL12
    Wei‐Shiung Lian, Jih‐Yang Ko, Yushan Chen, Huei-Jing Ke, Chin-Kuei Hsieh, Chung-Wen Kuo, Shao-Yu Wang, Bo-Wun Huang, Jung-Ge Tseng, Feng‐Sheng Wang · 2019 · Cell Death and Disease
86. Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
    Nicholas R. Fuggle, Cyrus C. Cooper, Nicholas C. Harvey, Nasser M. Al‐Daghri, Maria Luisa Brandi, Olivier Bruyère, Antonio Cano, Elaine Margaret Dennison, Adolfo Díez‐Pérez, Jean‐Marc Kaufman et al. · 2020 · Drugs
87. The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis
    Anne Sophie Sølling, Torben Harsløf, Bente Lomholt Langdahl · 2018 · Therapeutic Advances in Musculoskeletal Disease
88. Identification of Fibroblast Activation Protein as an Osteogenic Suppressor and Anti-osteoporosis Drug Target
    Hanjing Wei, Yanhua Xu, Yibin Wang, Liting Xu, Chunyang Mo, Liangzi Li, Bo Shen, Yao Sun, Pengzhen Cheng, Liu Yang et al. · 2020 · Cell Reports
89. Fracture risk assessment by the FRAX model
    Eugene Vincent McCloskey, Nicholas C. Harvey, Helena Johansson, Mattias Lorentzon, Enwu Liu, Liesbeth Vandenput, William Donald Leslie, John А. Kanis · 2021 · Climacteric
90. Anabolic therapy for osteoporosis: update on efficacy and safety
    Leonardo Bandeira, Edward Michael Lewiecki · 2022 · Archives of Endocrinology and Metabolism
91. Drug discovery of sclerostin inhibitors
    Sifan Yu, Dijie Li, Ning Zhang, Shuaijian Ni, Meiheng Sun, Luyao Wang, Huan Xiao, Dingdong Liu, Jin Liu, Yuanyuan Yu et al. · 2022 · Acta Pharmaceutica Sinica B
92. Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists
    Gill Holdsworth, Kevin J. Greenslade, Joby Jose, Zofia Stencel, Hishani Kirby, Adrian Moore, Hua Zhu Ke, Martyn K. Robinson · 2017 · Bone
93. Wnt signaling and bone regeneration: Can't have one without the other
    Philipp Leucht, Sooyeon Lee, Nury L. Yim · 2018 · Biomaterials
94. New therapeutic targets for osteoporosis
    Panagiotis G. Anagnostis, Nifon K. Gkekas, Michael E. Potoupnis, Eustathios I. Kenanidis, Eleftherios E. Tsiridis, Dimitrios G. Goulis · 2018 · Maturitas
95. Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture
    Felicia Cosman · 2020 · Endocrine Practice
96. Stem cell derived exosomes: microRNA therapy for age-related musculoskeletal disorders
    Xudong Yao, Wei Wei, Xiaozhao Wang, Li Chenglin, Mikael Björklund, Hongwei Ouyang · 2019 · Biomaterials
97. Pathophysiology of Medication‐Related Osteonecrosis of the Jaw—A Minireview
    Sotirios Tetradis, Matthew R. Allen, Salvatore L. Ruggiero · 2023 · JBMR Plus
98. Preclinical Rodent Models for Human Bone Disease, Including a Focus on Cortical Bone
    Natalie Y Y Koh, Justyna Jolanta Miszkiewicz, Mary Louise Fac, Natalie K. Y. Wee, Natalie A. Sims · 2024 · Endocrine Reviews
99. Bone Marrow Adipocyte: An Intimate Partner With Tumor Cells in Bone Metastasis
    Guojing Luo, Yuedong He, Xijie Yu · 2018 · Frontiers in Endocrinology
100. 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO)
     Serge Ferrari, Kurt Lippuner, Olivier Lamy, Christian Meier · 2020 · Swiss Medical Weekly